Helixmith Overview

  • Year Founded
  • 1996

Year Founded

  • Status
  • Public

  • Employees
  • 44

Employees

  • Stock Symbol
  • 084990

Stock Symbol

  • Investments
  • 3

  • Share Price
  • $2.10
  • (As of Friday Closing)

Helixmith General Information

Description

Helixmith Co Ltd, formerly ViroMed Co Ltd is active in the healthcare sector in Korea. The company specializes in developing pharmaceutical products for the treatment of diseases related to peripheral artery, coronary artery, cardiovascular system and neuropathy, cancer and allergy. Its suite of products includes protein/deoxyribonucleic acid (DNA)-based biopharmaceuticals, botanical drugs and natural pharmaceuticals.

Contact Information

Formerly Known As
ViroMedica Pacific, Viromed
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 21, Magokjungang 8-Ro 7-Gil
  • Gangseo-gu
  • Seoul, 07794
  • South Korea
+82
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Stock Exchange
KRX
Vertical(s)
Corporate Office
  • 21, Magokjungang 8-Ro 7-Gil
  • Gangseo-gu
  • Seoul, 07794
  • South Korea
+82

Helixmith Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Helixmith Stock Performance

As of 20-Jun-2025, Helixmith’s stock price is $2.10. Its current market cap is $96.8M with 46M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.10 $2.07 $1.42 - $3.66 $96.8M 46M 146K -$0.18

Helixmith Financials Summary

As of 31-Mar-2025, Helixmith has a trailing 12-month revenue of $3.65M.

In Thousands,
USD
TTM 31-Mar-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022
EV 18,383 32,586 186,997 334,615
Revenue 3,647 3,645 3,214 2,167
EBITDA (8,283) (10,876) (42,967) (25,371)
Net Income (8,345) (11,339) (49,018) (33,695)
Total Assets 100,040 101,081 176,366 201,172
Total Debt 165 143 15,696 16,288
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Helixmith Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Helixmith‘s full profile, request access.

Request a free trial

Helixmith Patents

Helixmith Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4516913-A1 Aav vector optimized for intrathecal administration into which hepatocyte growth factor gene is introduced Pending 27-Apr-2022
EP-4501312-A1 Liquid formulation pharmaceutical composition comprising plasmid dna Pending 24-Mar-2022
US-20220362298-A1 Chimeric antigen receptor comprising anti c-met antibody or antigen binding fragment thereof, and use thereof Pending 26-Sep-2019
EP-4039703-A1 Chimeric antigen receptor comprising anti c-met antibody or antigen binding fragment thereof, and use thereof Pending 26-Sep-2019
EP-4039703-A4 Chimeric antigen receptor comprising anti c-met antibody or antigen binding fragment thereof, and use thereof Pending 26-Sep-2019 C07K14/70521
To view Helixmith’s complete patent history, request access »

Helixmith Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Helixmith Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Helixmith‘s full profile, request access.

Request a free trial

Helixmith Investments & Acquisitions (3)

Helixmith’s most recent deal was a Corporate Asset Purchase with Vical (DNA Production Facility). The deal was made on 20-Aug-2018.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Vical (DNA Production Facility) 20-Aug-2018 Corporate Asset Purchase Buildings and Property
Wacker Biotech US 01-Aug-2018 Joint Venture BPO/Outsource Services
Helixir (Drug Discovery) 10-Nov-2009 Merger/Acquisition Pharmaceuticals
To view Helixmith’s complete investments and acquisitions history, request access »

Helixmith ESG

Risk Overview

Risk Rating

Updated September, 15, 2023

30.34 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,673

Rank

Percentile

Pharmaceuticals

Industry

of 844

Rank

Percentile

Biotechnology

Subindustry

of 366

Rank

Percentile

To view Helixmith’s complete esg history, request access »

Helixmith Exits (1)

Helixmith’s most recent exit was on 01-Aug-2018 from Wacker Biotech US. The exit was categorized as with 2 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
Wacker Biotech US 01-Aug-2018 Completed
  • 2 buyers
To view Helixmith’s complete exits history, request access »

Helixmith FAQs

  • When was Helixmith founded?

    Helixmith was founded in 1996.

  • Where is Helixmith headquartered?

    Helixmith is headquartered in Seoul, South Korea.

  • What is the size of Helixmith?

    Helixmith has 44 total employees.

  • What industry is Helixmith in?

    Helixmith’s primary industry is Biotechnology.

  • Is Helixmith a private or public company?

    Helixmith is a Public company.

  • What is Helixmith’s stock symbol?

    The ticker symbol for Helixmith is 084990.

  • What is the current stock price of Helixmith?

    As of 20-Jun-2025 the stock price of Helixmith is $2.10.

  • What is the current market cap of Helixmith?

    The current market capitalization of Helixmith is $96.8M.

  • What is Helixmith’s current revenue?

    The trailing twelve month revenue for Helixmith is $3.65M.

  • What is Helixmith’s annual earnings per share (EPS)?

    Helixmith’s EPS for 12 months was -$0.18.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »